最新ニュース Hologic (NASDAQ:HOLX) 株価情報

Hologic

Hologic manufactures proprietary products for the healthcare needs of women. The company operates in five segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.

Hologic Inc

News

Buybacks

HOLX

Hologic Intends To Enter Into An Accelerated Share Repurchase Agreement For $250M Of The Company's Common Stock.

Guidance

Hologic Sees FY25 Adj. EPS $4.25-$4.35, Revenue $4.15B-$4.20B; Sees Q1 Adj. EPS $1.00-$1.03, Revenue $1.025B-$1.035B

Earnings

Earnings Beats

Hologic Q4 2024 Adj. EPS $1.01, Inline, Sales $987.900M Beat $976.688M Estimate

The U.S. stock market struggled to gain momentum on Monday as investors remained cautious ahead of <a href="https://www.benzinga.com/topic/election-day">Election Day on Tuesday</a>. 
Vice President Kamala Harris holds a 1-point lead over ex-President Donald Trump, according to the New York Times national polling average; she has a 4-point lead among likely voters nationally, <a href="https://maristpoll.marist.edu/polls/u-s-presidential-contest-november-2024/">according to the latest PBS News/NPR/Marist poll</a>.
Betting markets, as tracked by the CFTC-regulated Kalshi, favor a Trump win at a 53% chance, <a href="https://www.benzinga.com/general/politics/24/11/41702729/harris-surges-in-prediction-markets-nabs-kalshi-lead-with-just-three-days-to-go">but with diminishing odds</a> compared to previous weeks. Also, the betting odds are susceptible to wild swings from so-called "whale" bettors, including one individual on Polymarket <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41463756/polymarket-to-review-user-base-in-light-of-whales-betting-millions-on-trump-election-win" target="_blank" rel="noreferrer noopener">who spent as much as</a> $43 million on a Trump victory.
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41717129/polymarkets-all-time-leading-trader-bets-over-500-000-on-kamala-harris-slams-nate-silver-f">Polymarket&#8217;s All-Time Leading Trader Bets Over $500,000 On Kamala Harris, Slams Nate Silver For Including &#8216;Fake Poll&#8217; Data In Model</a>
&#8220;Neither candidate holds a meaningful edge in enough states to win 270 electoral votes. In the history of modern polling, there's never been a race where the final polls showed such a close contest,&#8221; said Nate Cohn, chief political analyst for the New York Times. 
The S&amp;P 500 slipped 0.2%, while the Dow dropped 0.6%, hitting its lowest intraday level since mid-September. In contrast, small-cap stocks in the Russell 2000 outperformed, rising 1%. The Nasdaq 100 also retreated, dipping below the 20,000 mark.
Treasury yields fell by nearly 10 basis points as investors scaled back positions linked to Trump&#8217;s inflationary policies, such as high tariffs and more expansionary fiscal measures. The dollar also weakened, down 0.5%.
The increasing likelihood of a Harris victory gave a boost to solar and renewable energy stocks, with the Invesco Solar ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAN#NYSE">TAN</a>) climbing 3.6%. 
Oil and gas stocks also gained, as crude prices surged 3% after OPEC+ postponed an anticipated production hike. Exxon Mobil Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>) jumped 3%, marking its largest single-day gain since late June.
Gold held steady at $2,740, while Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) fell over 1%, dropping below $68,000.
<h3 class="wp-block-heading">Monday&#8217;s Performance In Major US Indices, ETFs</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day %chg</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,230.95</td>
<td>1.0%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,715.31</td>
<td>-0.2%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>19,978.22</td>
<td>-0.3%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>41,807.92</td>
<td>-0.6%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 12:45 p.m. ET</figcaption></figure>
According to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent110424&amp;t=be2bearmibe3na1">Benzinga Pro</a> data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) rose 0.1% to $570.22.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>)&nbsp;fell 0.5% to $418.44.</li>
<li>The tech-heavy Invesco QQQ Trust Series (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) fell 0.2% to $486.77.</li>
<li>The iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) rose 1.1% to $221.27.</li>
<li>The Energy Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) outperformed, rising 1.7%. The Utilities Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>) lagged, down 1.5%.</li>
</ul>
<h3 class="wp-block-heading">Monday&#8217;s Stock Movers</h3>
Stocks reacting to earnings reports included: 
<ul>
<li>Zoetis Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>), down 3.9%, </li>
<li>Constellation Energy Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CEG#NYSE">CEG</a>), down 10.5%, </li>
<li>Marriott International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAR#NASDAQ">MAR</a>), down 1.8%, </li>
<li>Fidelity National Information Services, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIS#NYSE">FIS</a>), down 0.4%, </li>
<li>Public Service Enterprise Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEG#NYSE">PEG</a>), down 5.9%, </li>
<li>TPG Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPG#NASDAQ">TPG</a>), down 5.5%. </li>
<li>Fox Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOX#NASDAQ">FOX</a>), up 3.7%, </li>
<li>YUM China Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YUMC#NYSE">YUMC</a>), up 7.9%, </li>
<li>Loews Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/L#NYSE">L</a>), down 4.8%, </li>
</ul>
Stocks slated to report earnings after the close are Vertex Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>), Palantir Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>), NXP Semiconductors NV (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXPI#NASDAQ">NXPI</a>), Diamondback Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FANG#NASDAQ">FANG</a>), American International Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIG#NYSE">AIG</a>), Illumina Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>), Hologic Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) and Astera Labs Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAB#NASDAQ">ALAB</a>).
Now Read:
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41702887/harris-takes-lead-in-red-state-iowa-in-shock-poll">Harris Takes Lead In Red State Iowa In Shock Poll</a></li>
</ul>
Image: Shutterstock

Equities

Large Cap

Macro Economic Events

Mid Cap

Broad U.S. Equity ETFs

Politics

Economics

Tech

ETFs

$BTC

ALAB

SPDR Dow Jones Industrial Average ETF Trust

FANG

ILMN

NXPI

PLTR

VRTX

Select Sector SPDR-Consumer Discretionary

YUMC

Wall Street Struggles Ahead Of Election Day, Energy Sector Outperforms, Solar Stocks Rise: What's Driving Markets Monday?

On Friday, the FDA warned against using Hologic Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) BioZorb Marker products and urged healthcare facilities to return all unused lots.
This follows Hologic&#8217;s voluntary <a target="_blank" href="https://www.hologic.com/biozorb-3d-bioabsorbable-marker-important-recall-information" rel="noreferrer noopener">recall</a> of the BioZorb Marker and BioZorb LP Marker, implantable devices intended for marking sites in soft tissues like breast tissue.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41319059/hologic-adds-gynesonics-sonata-system-in-350m-acquisition-to-boost-fibroid-treatmen" rel="noreferrer noopener">Hologic Adds Gynesonics&#8217; Sonata System In $350M Acquisition To Boost Fibroid Treatments</a>
The recall comes in response to reports of serious adverse events in patients, including pain, infection, and device migration, among others.
The BioZorb Marker, introduced as a radiographic tool for marking soft tissue sites, consists of a dissolvable plastic component and a permanent titanium metal part.
While it helps mark areas for future medical procedures, the FDA emphasized it is not approved to fill tissue space, enhance cosmetic results, or serve as a radiation treatment marker.
In February, Hologic <a target="_blank" href="https://www.fda.gov/medical-devices/safety-communications/update-do-not-use-biozorb-marker-implantable-radiographic-marker-devices-fda-safety-communication#:~:text=The%20FDA%20has%20received%20reports,from%20feeling%20the%20device%20in" rel="noreferrer noopener">alerted</a> healthcare providers about potential risks, but the recent recall expands on that, mandating the return of all unused BioZorb devices as a preventive action.
The FDA and Hologic outlined essential steps for healthcare providers, recommending against implanting BioZorb Markers, quarantining existing devices, and discussing associated risks with patients who already have the implant.
This guidance aims to ensure patients&#8217; safety, given the documented complications of BioZorb devices in breast tissue, which range from minor rashes to severe issues such as device erosion through the skin.
Since BioZorb&#8217;s launch in 2015, approximately 91,531 units have been sold, with 399 complaints reported as of October 2024.
Among these, 188 cases were linked to adverse effects.
Price Action: HOLX stock is down 0.95% at $80.14 at the last check on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/10/41552265/johnson-johnsons-blockbuster-drug-tremfya-clears-plaque-psoriasis-with-lesions-covering-bodys-sma" target="_blank" rel="noreferrer noopener">Johnson &amp; Johnson&#8217;s Blockbuster Drug Tremfya Clears Plaque Psoriasis With Lesions Covering Body&#8217;s Smaller Areas</a>.</li>
</ul>

Health Care

General

Hologic Recalls Soft Tissue Marker Device BioZorb, FDA Issues Warning After Almost 400 Complaints

<a href="https://www.fda.gov/medical-devices/safety-communications/update-do-not-use-biozorb-marker-implantable-radiographic-marker-devices-fda-safety-communication#:~:text=The%20FDA%20has%20received%20reports,from%20feeling%20the%20device%20in">https://www.fda.gov/medical-devices/safety-communications/update-do-not-use-biozorb-marker-implantable-radiographic-marker-devices-fda-safety-communication#:~:text=The%20FDA%20has%20received%20reports,from%20feeling%20the%20device%20in</a>
&nbsp;
Date Issued: October 25, 2024
The U.S. Food and Drug Administration (FDA) is alerting consumers, health care providers and health care facilities not to use BioZorb Markers and BioZorb LP Markers (hereafter referred to simply as BioZorb Markers) by Hologic Inc.
On October 25, 2024, Hologic <a href="https://www.hologic.com/biozorb-3d-bioabsorbable-marker-important-recall-information">announced</a><a href="http://www.fda.gov/about-fda/website-policies/website-disclaimer">External Link Disclaimer</a> a voluntary recall for removal of all lots of unused BioZorb Markers. The recall is due to reports of serious adverse events occurring in patients who had the devices implanted in breast tissue.
The FDA is issuing this communication to help ensure you are aware of the manufacturer&#39;s most recent recall notice and the recommended actions.
<h2>Recommendations for Patients with a BioZorb Marker and their Caregivers</h2>
<ul>
<li>If you experience any adverse events with your BioZorb Marker, please contact your health care provider.</li>
<li>There is no need to have the device removed from your body (explanted) unless advised by your health care provider.</li>
<li>If your provider is planning radiation therapy treatments, discuss the possible risks with your provider. The FDA has not cleared or approved the use of BioZorb Marker as a marker for radiation treatment.</li>
<li><a href="https://www.fda.gov/medical-devices/safety-communications/update-do-not-use-biozorb-marker-implantable-radiographic-marker-devices-fda-safety-communication#report">Report any problems or complications</a> with your BioZorb Marker to the FDA.</li>
</ul>
<h2>Recommendations for Health Care Providers and Facilities</h2>
<ul>
<li>Do not implant BioZorb Markers.</li>
<li>Quarantine and return all lots of unused BioZorb Markers to Hologic.</li>
<li>Review and discuss the Recommendations for Patients above with your patients who have a BioZorb Marker.</li>
<li>Be aware of reports of serious adverse events following the placement of BioZorb Marker devices in breast tissue.</li>
<li>Continue to monitor patients who have an implanted BioZorb Marker for signs of any adverse events.</li>
<li>Be aware the FDA has not cleared or approved the use of BioZorb Markers to fill space in the tissue or to improve cosmetic outcomes after procedures, or as a marker for radiation treatment.</li>
<li><a href="https://www.fda.gov/medical-devices/safety-communications/update-do-not-use-biozorb-marker-implantable-radiographic-marker-devices-fda-safety-communication#report">Report any problems or complications</a> your patients experience following the placement of BioZorb Marker devices to the FDA.</li>
</ul>
<h2>Device Description</h2>
BioZorb Markers are implantable devices used in soft tissue sites, including breast tissue. BioZorb Markers have two parts: a plastic component that is intended to be dissolved completely in the patient&#39;s body in one year or longer, and a titanium metal component that is permanent.
The BioZorb Marker is indicated for radiographic marking of sites in soft tissue. In addition, the BioZorb Marker is indicated in situations where the soft tissue site needs to be marked for future medical procedures.
The BioZorb Marker is not indicated to improve cosmetic outcomes after procedures, fill space in the tissue, or to be a marker for radiation treatment.
<h2>Risks Associated with BioZorb Marker in Breast Tissue</h2>
Reported complications and adverse events with BioZorb Marker that include serious injuries are:
<ul>
<li>Pain</li>
<li>Infection</li>
<li>Rash</li>
<li>Device migration (moving out of position)</li>
<li>Device erosion (breaking through the skin)</li>
<li>Seroma (fluid buildup)</li>
<li>Discomfort</li>
<li>Other complications from feeling the device in the breast</li>
</ul>
In some instances, additional medical treatment, including having the device removed from the body (explantation), was needed.
<h2>FDA Actions</h2>
The FDA will continue to work with Hologic to monitor reports of problems with BioZorb Markers, including issues that may develop over time.
The FDA will continue to keep the public informed if significant new information becomes available.

Biotech

FDA In Safety Communication Says Do Not Use BioZorb Marker Implantable Radiographic Marker Devices; Hologic Recall Due To Reports Of Serious Adverse Events Occurring In Patients Who Had BioZorb Marker Devices Implanted In Breast Tissue

Needham analyst Mike Matson reiterates Hologic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) with a Buy and maintains $90 price target.

Price Target

Reiteration

Analyst Ratings

Needham Reiterates Buy on Hologic, Maintains $90 Price Target

On Monday, Hologic Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) agreed to acquire&nbsp;&nbsp;Gynesonics, Inc. for <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/b41310959/hologic-to-acquire-gynesonics-developer-of-minimally-invasive-solutions-for-womens-health" rel="noreferrer noopener">approximately $350 million</a>.
Gynesonics is a privately held medical device company that develops minimally invasive solutions for women&#8217;s health.
California-based Gynesonics develops and sells the Sonata System, a technology intended for diagnostic intrauterine imaging and transcervical treatment of certain symptomatic uterine fibroids, including those associated with heavy menstrual bleeding.
The Sonata System combines real-time intrauterine ultrasound guidance with targeted radiofrequency ablation in an incisionless procedure.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/06/39534064/womens-health-focused-hologic-has-significant-capacity-for-expansion-via-m-a-bullis" rel="noreferrer noopener">Women&#8217;s Health-Focused Hologic Has Significant Capacity For Expansion Via M&amp;A, Bullish Analyst Says</a>.
William Blair writes that Sonata System&#8217;s approach differs from Hologic&#8217;s Acessa device/ procedure, which delivers imaging and radiofrequency heat through two small abdominal incisions.
Hologic&#8217;s MyoSure device/procedure is also a solution for fibroid removal, though this is done through tissue removal rather than tissue ablation. &#8220;We believe that while there could become overlap amongst these products, having different solutions in Hologic&#8217;s product suite should allow for greater adoption,&#8221; the analyst writes.
Given the target&#8217;s profile, William Blair analyst says it is unlikely that the deal will significantly impact Hologic&#8217;s objective of maintaining operating margins in the low-30% range.
Hologic is scheduled to report fiscal fourth-quarter<a target="_blank" href="https://www.benzinga.com//node/41183593" rel="noreferrer noopener"> earnings in early November.</a>
As per data from Benzinga Pro, analysts expect adjusted EPS of $1.01 and <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">revenues of $977.05 million</a>.
The analyst adds that revenue and earnings forecasts and consensus estimates have decreased in the past month as the company signals a more cautious stance on non-core elements like net interest expense.
The company is well-positioned to achieve mid-single-digit organic revenue growth, with earnings growth projected to outpace that in the high-single- to low-double-digit percentage range over time.
Several factors could drive earnings within this expected range, and shares are trading at a fair multiple of just under 19 times 2025 earnings.
The analyst reiterates <a target="_blank" href="https://www.benzinga.com/quote/HOLX/analyst-ratings" rel="noreferrer noopener">the Outperform rating</a>.
Price Action: HOLX stock is up 1.54% at $81.04 at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41317937/qualcomm-set-for-50-surge-in-snapdragon-8-gen-4-shipments-by-late-2024-analyst-pred" target="_blank" rel="noreferrer noopener">Qualcomm Set For 50% Surge In Snapdragon 8 Gen 4 Shipments By Late 2024, Analyst Predicts</a>.</li>
</ul>

Analyst Color

Trading Ideas

Hologic Adds Gynesonics' Sonata System In $350M Acquisition To Boost Fibroid Treatments

Hologic To Acquire Women's Health Medical Device Co. Gynesonics For ~$350M

Leerink Partners analyst Puneet Souda maintains Hologic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) with a Outperform and lowers the price target from $95 to $90.

Leerink Partners Maintains Outperform on Hologic, Lowers Price Target to $90

10 analysts have shared their evaluations of Hologic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Hologic, presenting an average target of $86.6, a high estimate of $95.00, and a low estimate of $78.00. Observing a 0.7% increase, the current average has risen from the previous average price target of $86.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1728065025_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The perception of Hologic by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anthony Petrone</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$90.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Vijay Kumar</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$82.00</td>
<td>$78.00</td>
</tr>
<tr>
<td>Patrick Donnelly</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$85.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Conor McNamara</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$82.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Mason Carrico</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$92.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Vijay Kumar</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$78.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>Casey Woodring</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$95.00</td>
<td>$91.00</td>
</tr>
<tr>
<td>Conor McNamara</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$82.00</td>
<td>$81.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Hologic. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Hologic compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Hologic's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Hologic's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/HOLX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Hologic analyst ratings.</a>
<h2>Unveiling the Story Behind Hologic</h2>
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in five segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.
<h3>Hologic: A Financial Overview</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Hologic's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 2.74%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Hologic's net margin excels beyond industry benchmarks, reaching 19.23%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Hologic's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 3.97% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Hologic's ROA stands out, surpassing industry averages. With an impressive ROA of 2.21%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Hologic's debt-to-equity ratio is below the industry average at 0.52, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Assessing Hologic: Insights From 10 Financial Analysts

Mizuho analyst Anthony Petrone maintains Hologic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) with a Outperform and raises the price target from $85 to $90.

Mizuho Maintains Outperform on Hologic, Raises Price Target to $90

Evercore ISI Group analyst Vijay Kumar maintains Hologic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) with a In-Line and raises the price target from $78 to $82.

Evercore ISI Group Maintains In-Line on Hologic, Raises Price Target to $82

Citigroup analyst Patrick Donnelly downgrades Hologic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) from Buy to Neutral and lowers the price target from $95 to $85.

Downgrades

Citigroup Downgrades Hologic to Neutral, Lowers Price Target to $85

Hologic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) has outperformed the market over the past 20 years by 6.54% on an annualized basis producing an average annual return of 14.96%. Currently, Hologic has a market capitalization of $18.77 billion. 
Buying $100 In HOLX: If an investor had bought $100 of HOLX stock 20 years ago, it would be worth $1,619.80 today based on a price of $80.82 for HOLX at the time of writing.
<h3>Hologic's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727719213_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In This Stock 20 Years Ago Would Be Worth $1,600 Today

Hologic (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/holx#NASDAQ">HOLX</a>) has been gaining from new strategic product launches across Diagnostics and Breast Health. However, macroeconomic issues and unfavorable FX headwinds continue to impede growth. The stock carries a Zacks Rank #3 (Hold) currently.
<h2>Major Factors Driving HOLX Stock Growth</h2>
Among Hologic&#39;s advanced diagnostic products, primary revenue-generating ones are molecular diagnostic assays, which run on advanced instrumentation systems (Panther, Panther Fusion and Tigris), ThinPrep cytology system and the Rapid Fetal Fibronectin Test. With solid 10.5% growth, excluding COVID-19 sales in the fiscal third quarter of 2024, the Molecular Diagnostics business has consistently maintained high-single to double-digit gains in 13 of the last 15 quarters. Growth continues to be driven by the ongoing adoption and utilization of the broad menu in the Panther platform.
In Breast Health, Hologic expanded its product offering from imaging to cover the continuum of breast cancer care, including biopsy and surgery. The business is thriving primarily in the burgeoning spaces of radiology, breast surgery, pathology and treatment, with key profitable offerings such as 3D digital mammography systems, image analytics software utilizing artificial intelligence, ultrasound imaging and minimally invasive breast biopsy guidance systems. In the third quarter of fiscal 2024, revenues increased 7.1% (excluding the divested SSI business), driven by domestic and international growth of 7.2% and 12.1%, respectively.
The company&#39;s international sales have been a major catalyst in the past few years, growing 5.1% year over year in the third quarter of fiscal 2024. Molecular STI testing, cytology and MyoSure experienced strong growth in the global markets. However, the company perceives it as still in the early phase of utilizing its expanded Panther installed base. Similarly, while international cytology and STI testing have more dominant U.S. revenues, they are expected to become meaningful revenue drivers in the international markets with time.
In order to streamline its operations and reduce the cost of revenues, Hologic has adopted a few significant strategies over the past few years. The company has invested deliberately and opportunistically in commercial areas where management has recognized a good return. These include Hologic&#39;s Genius marketing campaign in Breast Health, cervical cancer co-testing initiatives in Diagnostics, along with efforts to gain competitive market share with NovaSure.
<div class="chart_embed">
<h2>Hologic, Inc. Price</h2>
<img alt="Hologic, Inc. Price" src="https://staticx-tuner.zacks.com/images/charts/2d/1727441408.png" style="height:251px; width:538px" title="" />
Hologic, Inc. price | Hologic, Inc. Quote
Per management, these strategic initiatives are already paying off through increased brand awareness, market share gains, and price stability, all of which will contribute to the company&#39;s higher sales. In the third quarter of fiscal 2024, the company was awarded the Innovative Technology Contract by Vizient, which expands access to its Surgical product lineup. The contract recognized Hologic&#39;s CoolSeal advanced energy portfolio and JustRight 5 mm stapler for their potential to enhance clinical care, patient safety and healthcare worker safety or improve business operations of healthcare organizations.
</div>
The stock has gained 12.2% year to date, compared with the industry&#39;s 7.6% rise. With the company currently focusing on the expansion of diagnostics assay and breast health offerings in global markets, we expect the stock to continue its upward movement in the coming days.
<h2>Major Downsides for HOLX</h2>
Continued concerns about the systemic impact of potential long-term and widespread recession have added to market volatility and diminished expectations for economic growth. The effect of the worldwide political and social uncertainty, including the impact on trade regulations and tariffs, economic disruptions as well as the ongoing supply chain constraints, have reportedly hampered the costs and sales of Hologic&#39;s products in certain countries in recent times. In the third quarter of fiscal 2024, Hologic&#39;s cost of revenues (product, service and other) rose about 1.9% year over year, while selling, general and administration expenses increased 4.2%.
These uncertainties surrounding global economic conditions and financial markets may cause medical equipment purchasers to decrease their medical health insurance premiums and procurement activities. Additionally, higher unemployment rates and health insurance premiums, co-payments and deductibles may result in cost-conscious consumers making fewer trips to their physicians and specialists, affecting the demand for the company&#39;s products and procedures.
We remain worried about the significant challenges Hologic faces owing to unfavorable foreign currency impact that has been adversely impacting the company&#39;s overall performance in the past few quarters. The company&#39;s international sales are often denominated in foreign currencies, including the euro, UK pound and renminbi. Changes in currency exchange rates, particularly the increase in the value of the dollar against any such foreign currencies, may reduce the reported value of Hologic&#39;s revenues outside the United States and associated cash flows. The company expects about $3 million adverse currency impact in the fourth quarter.
For several quarters in a row, declining COVID-19 assay revenues have been a headwind to some of the company&#39;s key performance metrics. Although the company returned to growth in the fiscal third quarter, the potential impact of the COVID-19 sales downturn still lingers.
Hologic&#39;s fiscal 2024 guidance assumes $70 million from COVID-19 assay sales, including $7 million in the fourth quarter of fiscal 2024. Overall, revenues from COVID-19-related items are expected to be approximately $105 million in fiscal 2024.
<h2>Key Picks</h2>
Some better-ranked stocks in the broader medical space are TransMedics Group (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tmdx#NASDAQ">TMDX</a>), AxoGen (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/axgn#NASDAQ">AXGN</a>) and OrthoPediatrics (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/kids#NASDAQ">KIDS</a>). While TransMedics sports a Zacks Rank #1 (Strong Buy) at present, AxoGen and OrthoPediatrics carry a Zacks Rank #2 (Buy) each.
Estimates for TransMedics&#39; 2024 earnings per share have moved up 2.5% to $1.23 in the past 30 days. Shares of the company have soared 156.5% in the past year compared with the industry&#39;s 17.5% growth. TMDX&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 287.50%. In the last reported quarter, it delivered an earnings surprise of 66.67%.
Estimates for AxoGen&#39;s 2024 loss per share have remained constant at 1 cent in the past 30 days. Shares of the company have surged 165.9% in the past year, compared with the industry&#39;s 17.6% growth. AXGN&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 96.5%. In the last reported quarter, it delivered an earnings surprise of 200%.
Estimates for OrthoPediatrics&#39; 2024 loss per share have declined to 92 cents from 96 cents in the past 30 days. In the past year, shares of KIDS have lost 17.1% against the industry&#39;s 20.8% growth. In the last reported quarter, it delivered an earnings surprise of 25.81%. Its earnings surpassed estimates in each of the trailing four quarters, the average surprise being 26.81%.
<a href="https://www.zacks.com/stock/news/2342713/holx-stock-gains-from-new-offerings-despite-macro-issues?cid=CS-BENZ-FT-analyst_blog|zer_report_update-2342713">To read this article on Zacks.com click here.</a>

Government

Regulations

Offerings

Contracts

Small Cap

Management

Markets

AXGN

KIDS

TMDX

HOLX Stock Gains From New Offerings Despite Macro Issues

Ratings for Hologic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) were provided by 9 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $85.78, a high estimate of $95.00, and a low estimate of $76.00. This upward trend is apparent, with the current average reflecting a 0.92% increase from the previous average price target of $85.00.
<img src="https://www.benzinga.com/files/images/story/2024/1726578028_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Hologic. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Conor McNamara</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$82.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Mason Carrico</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$92.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Vijay Kumar</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$78.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>Casey Woodring</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$95.00</td>
<td>$91.00</td>
</tr>
<tr>
<td>Conor McNamara</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$82.00</td>
<td>$81.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Vijay Kumar</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$76.00</td>
<td>$78.00</td>
</tr>
<tr>
<td>Mason Carrico</td>
<td>Stephens &amp; Co.</td>
<td>Announces</td>
<td>Overweight</td>
<td>$87.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Hologic. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Hologic compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Hologic's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
For valuable insights into Hologic's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/HOLX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Hologic analyst ratings.</a>
<h2>Discovering Hologic: A Closer Look</h2>
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in five segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.
<h3>Key Indicators: Hologic's Financial Health</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Hologic's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 2.74%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Hologic's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 19.23% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Hologic's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 3.97%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Hologic's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 2.21%, the company showcases efficient use of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 0.52, Hologic adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>What Are Analyst Ratings?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Critical Insights From Hologic Analyst Ratings: What You Need To Know

Hologic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) has outperformed the market over the past 20 years by 6.49% on an annualized basis producing an average annual return of 14.78%. Currently, Hologic has a market capitalization of $18.58 billion. 
Buying $1000 In HOLX: If an investor had bought $1000 of HOLX stock 20 years ago, it would be worth $16,165.24 today based on a price of $80.01 for HOLX at the time of writing.
<h3>Hologic's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726149845_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Hologic Stock In The Last 20 Years

Hologic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) has outperformed the market over the past 20 years by 6.49% on an annualized basis producing an average annual return of 14.78%. Currently, Hologic has a market capitalization of $18.58 billion. 
Buying $1000 In HOLX: If an investor had bought $1000 of HOLX stock 20 years ago, it would be worth $16,165.24 today based on a price of $80.01 for HOLX at the time of writing.
<h3>Hologic's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726149789_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Hologic: Continued Room Amidst Bolt-On M&A Efforts

Here are the major earnings after the close today

Notable companies reporting after the market close, with earnings consensus, include Vertex Pharmaceuticals (VRTX), consensus $4.14… Palantir (PLTR...

Notable companies reporting after market close

Hologic GAAP EPS of $1.01 beats by $0.18, revenue of $987.9M beats by $11.21M

Sees FY25 revenue $4.15B-$4.20B, consensus $4.21B Published first on TheFly – the ultimate source for real-time, market-moving breaking financial n...

Hologic sees FY25 EPS $4.25-$4.35, consensus $4.32

Check out this evening's top movers from around Wall Street, compiled by The Fly.&nbsp;&nbsp; HIGHER AFTER EARNINGS – QuinStreet&nbsp;(QNST)&nbsp;u...

Closing Bell Movers: Palantir jumps 13% after results

Hologic, Inc. (HOLX) Q4 2024 Earnings Call Transcript

Hologic ( ($HOLX) ) has released its Q4 earnings. Here is a breakdown of the information Hologic presented to its investors. Hologic, Inc. is a med...

Hologic Reports Robust Q4 2024 Financial Growth

Analyst Michael Matson from Needham reiterated a Buy rating on Hologic (HOLX – Research Report) and keeping the price target at $90.00. Michael Mat...

Hologic's Strong Performance and Future Growth Prospects Justify Buy Rating

In a report released yesterday, Conor McNamara from RBC Capital maintained a Hold rating on Hologic (HOLX – Research Report), with a price target o...

RBC Capital Reaffirms Their Hold Rating on Hologic (HOLX)

ABCL

ANDE

AOSL

APLE

AQST

ATUS

AZPN

BCOV

BOOM

BOWL

BWXT

CDNA

CENX

CLLS

CRGY

CRUS

CSTL

DLTR

EGHT

EVER

FWRD

GKOS

HDSN

HIMS

ICHR

INSP

ITUB

LSCC

METC

NTST

NVTS

OTTR

PARR

QNST

SLAB

VMEO

WYNN

Press Releases

Hologic to Announce Financial Results for the Third Quarter of Fiscal 2024 on Monday, July 29, 2024

72 Million American Women Have Skipped or Delayed Vital Screenings

Hologic Completes Acquisition of Endomagnetics Ltd

Hologic Announces Financial Results for Third Quarter of Fiscal 2024

Hologic to Webcast Presentation at the Morgan Stanley 22nd Annual Global Healthcare Conference

Hologic Unveils #BustTheMyth Campaign to Debunk Breast Cancer Myths and Empower Women This Breast Cancer Awareness Month

Hologic to Announce Financial Results for the Fourth Quarter of Fiscal 2024 on Monday, November 4, 2024

Hologic to Acquire Gynesonics, Developer of Minimally Invasive Solutions for Women's Health

Opinion

Breast Cancer Awareness Month Sees Biotech Advancements and Worrying Trends for Young Women

Comments

Hologic

ニュース

最新ニュース Hologic (NASDAQ:HOLX) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル